NewsWhore
10-26-2011, 03:51 AM
<img alt="" height="1" width="1" />
Merck KGaA Third-Quarter Profit Climbs 7.5%, Beating Analyst Estimates (http://news.google.com/news/url?sa=t&fd=R&usg=AFQjCNEpXKLst9qH9PskIbiji6_YOOo6Yw&url=http://www.bloomberg.com/news/2011-10-26/merck-kgaa-third-quarter-profit-rises-7-5-beating-estimates.html)
Bloomberg
Sales of MS therapy Rebif advanced 8.4 percent, excluding special effects such as currency shifts, to 426 million euros. Revenue from Erbitux on that basis increased 4.7 percent to 218 million euros. Sales at the Merck Millipore equipment, ...
and more » (http://news.google.com/news/more?ned=us&ncl=dx9zTB6gltsIKvM)
More... (http://news.google.com/news/url?sa=t&fd=R&usg=AFQjCNEpXKLst9qH9PskIbiji6_YOOo6Yw&url=http://www.bloomberg.com/news/2011-10-26/merck-kgaa-third-quarter-profit-rises-7-5-beating-estimates.html)
Merck KGaA Third-Quarter Profit Climbs 7.5%, Beating Analyst Estimates (http://news.google.com/news/url?sa=t&fd=R&usg=AFQjCNEpXKLst9qH9PskIbiji6_YOOo6Yw&url=http://www.bloomberg.com/news/2011-10-26/merck-kgaa-third-quarter-profit-rises-7-5-beating-estimates.html)
Bloomberg
Sales of MS therapy Rebif advanced 8.4 percent, excluding special effects such as currency shifts, to 426 million euros. Revenue from Erbitux on that basis increased 4.7 percent to 218 million euros. Sales at the Merck Millipore equipment, ...
and more » (http://news.google.com/news/more?ned=us&ncl=dx9zTB6gltsIKvM)
More... (http://news.google.com/news/url?sa=t&fd=R&usg=AFQjCNEpXKLst9qH9PskIbiji6_YOOo6Yw&url=http://www.bloomberg.com/news/2011-10-26/merck-kgaa-third-quarter-profit-rises-7-5-beating-estimates.html)